Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Root Extract from Traditional Chinese Medicinal Plant Shows Promise as Pain Reliever

By BiotechDaily International staff writers
Posted on 13 Jan 2014
Image: Corydalis yanhusuo plants and isolated rhizomes (inset) (Photo courtesy of Duoclieu, Vietnam).
Image: Corydalis yanhusuo plants and isolated rhizomes (inset) (Photo courtesy of Duoclieu, Vietnam).
A compound isolated from the roots of the traditional Chinese medicinal plant Corydalis yanhusuo has been found to be effective at relieving acute, inflammatory, and neuropathic pains.

Investigators at the University of California, Irvine (USA) and their collaborators at the Dalian Institute of Chemical Physics (China) isolated dehydrocorybulbine (DHCB) from the roots of C. yanhusuo, a flowering herbal plant that grows in Siberia, Northern China, and Japan. Extracts prepared from the roots of this plant have been used for many hundreds of years to alleviate menstrual cramps, chest pain, and abdominal pain.

The investigators tested DHCB in a rodent model. They reported in the January 2, 2014, online edition of the journal Current Biology that it displayed moderate dopamine receptor-antagonist activities. It was effective against inflammatory pain as well as injury-induced neuropathic pain and did not generate the sort of tolerance that develops with continued use of most conventional pain relievers, such as morphine.

Despite the promising results so far obtained, toxicity levels of purified DHCB remain to be established. While purified DHCB is not currently available, it is a component of the C. yanhusuo root or extracts that can be purchased in health stores or online.

“Today the pharmaceutical industry struggles to find new drugs. Yet for centuries people have used herbal remedies to address myriad health conditions, including pain. Our objective was to identify compounds in these herbal remedies that may help us discover new ways to treat health problems,” said senior author Dr. Olivier Civelli, professor of neuropharmacology at the University of California, Irvine. “We are excited that this one shows promise as an effective pharmaceutical. It also shows a different way to understand the pain mechanism.”

Related Links:

University of California, Irvine 
Dalian Institute of Chemical Physics



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.